Sign in

    Edward Ridley-Day

    Research Analyst at Redburn

    Edward Ridley-Day is Managing Director and Head of Global MedTech & Life Science Equipment Research at Redburn Atlantic, specializing in equity research for healthcare and medical technology sectors. He covers major companies including Hologic, Inc. and Edwards Lifesciences, consistently delivering unique insights and alpha-generating calls backed by nearly 20 years of industry experience. Ridley-Day began his career at Lehman Brothers in 2005 as Vice President, followed by Director roles at Barclays Capital, Merrill Lynch, and Nomura, joining Redburn in 2016 and attaining Managing Director status in 2019. He holds a degree from The University of Edinburgh and is recognized for his expertise in equities, financial modeling, and portfolio management; however, specific securities licenses and regulatory registrations are not publicly indicated.

    Edward Ridley-Day's questions to KONINKLIJKE PHILIPS (PHG) leadership

    Edward Ridley-Day's questions to KONINKLIJKE PHILIPS (PHG) leadership • Q2 2024

    Question

    Edward Ridley-Day of Redburn requested more color on the growth of the Ultrasound business excluding China and asked about the revenue growth trajectory for the Image-Guided Therapy (IGT) business.

    Answer

    CFO Abhijit Bhattacharya explained that Ultrasound growth ex-China would also show a decline due to the massive supplies and over 30% growth seen in H1 2023 as the company cleared supply chain backlogs. For IGT, he noted a slow recovery and a good quarter, but does not expect the business to be in double-digit growth territory for the full year, with its performance included in the overall D&T guidance.

    Ask Fintool Equity Research AI